首页 / 院系成果 / 成果详情页

Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome  期刊论文  

  • 编号：
    6695eb22-4318-4ae9-8a60-da9f037c6a22
  • 作者：
    Zhuge, Yuzheng(诸葛宇征)#*[1]Liu, Yulan(刘玉兰)*[2]Xie, Weifen[3];Zou, Xiaoping[1];Xu, Jianming[5];Wang, Jiyao[4];Bai, Wenyuan[6];Chen, Dongfeng[7];Chen, Jun[8];Chen, Ligang[9];Feng, Ying;Gao, Yanjing[10];Han, Hao[11];He, Jian[12];Hu, Xiqi[13];Huang, Shuling[1];Jiang, Haixing[14];Li, Liangping[15];Liu, Jie[16];Lu, Lungen[17];Ma, Xiong[18];Mi, Yuqiang[19];Nie, Yongzhan[20];Shen, Wei[21];Shen, Xizhong[4];Tang, Yongjin;Tian, De'an[22];Wang, Hongling[23];Wang, Jiangbin(王江滨)[24]Wang, Yi[1];Xu, Youqing[25];Xu, Zhaomin[1];Xu, Guoqiang[26];Yang, Jian[11];Yang, Li[27];Yang, Ling[28];Yang, Yunsheng[29];Zhang, Feng[1];Zhang, Ming[1];Zhang, Wei[1];Zhou, Xinmin[20];Zhu, Bin[12];Zhu, Xuan[30];
  • 语种：
    英文
  • 期刊：
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ISSN：0815-9319 2019 年 34 卷 4 期 (634 - 642) ; APR
  • 收录：
     
  • 关键词：
    hepatic sinusoidal obstruction syndrome Nanjing criteria pyrrolidine alkaloid
  • 摘要：

    Hepatic sinusoidal obstruction syndrome (HSOS) is a hepatic vascular disease presenting with abdominal distension, pain in the hepatic region, ascites, jaundice, and hepatomegaly. In China, this disease is often associated with the oral intake of plants that contain pyrrolidine alkaloids. The existing guidelines are limited to HSOS associated with hematopoietic stem cell transplantation in Western countries. The Hepatobiliary Diseases Committee of the Chinese Society of Gastroenterology convened an expert consensus conference on the diagnosis and treatment of PA-HSOS to evaluate current research in China and abroad. The "Nanjing criteria" developed by the committee to diagnose PA-HSOS include a confirmed history of PA-containing plant use and (i) abdominal distention and/or pain in the hepatic region, hepatomegaly, and ascites; (ii) elevation of serum total bilirubin or abnormal laboratory liver tests; (iii) evidence on enhanced computed tomography or magnetic resonance imaging; or (iv) pathological evidence that rules out other known causes of liver injury. Supportive symptomatic treatment, anticoagulant therapy, and placement of a transjugular intrahepatic portosystemic shunt for patients who do not respond to medical treatment are effective for the treatment of PA-HSOS. The benefits of glucocorticoids and prostaglandin E1 in PA-HSOS are not clear.

  • 推荐引用方式
    GB/T 7714：
    Zhuge Yuzheng,Liu Yulan,Xie Weifen, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome [J].JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2019,34(4):634-642.
  • APA：
    Zhuge Yuzheng,Liu Yulan,Xie Weifen,Zou Xiaoping,&Zhu Xuan.(2019).Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome .JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,34(4):634-642.
  • MLA：
    Zhuge Yuzheng, et al. "Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome" .JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 34,4(2019):634-642.
  • 条目包含文件：
    文件类型：PDF,文件大小：
    正在加载全文
浏览次数：182 下载次数：0
分享到：
浏览次数：182
下载次数：0
打印次数：0

网站总浏览量： 次   

Copyright © 中日联谊医院

技术支持：北京同舟云网络信息技术有限公司

浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部